We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generic Drugmakers Blast FDA’s Decision To Award Teva 180-Day Celebrex Exclusivity
Generic Drugmakers Blast FDA’s Decision To Award Teva 180-Day Celebrex Exclusivity
Mylan and Actavis are challenging the FDA’s April 24 decision to grant 180-day marketing exclusivity to Teva for a generic version of the blockbuster arthritis drug Celebrex.